Emcure Pharmaceuticals Ltd (EMCURE) — Capital Reinvestment Ratio
Latest as of September 2025:
0.50x
Emcure Pharmaceuticals Ltd (EMCURE) has a Capital Reinvestment Ratio of 0.50x as of September 2025, meaning it reinvests 1% of its operating cash flow (Rs2.56 Billion) in capital expenditures (Rs1.29 Billion). See EMCURE free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.50x
Capex / Operating Cash Flow
Operating Cash Flow
Rs2.56 Billion
INR
Capital Expenditures
Rs1.29 Billion
INR
Data as of
Sep 2025
Most recent filing
Emcure Pharmaceuticals Ltd Capital Reinvestment Ratio (2022–2026)
This chart tracks Emcure Pharmaceuticals Ltd's Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for Emcure Pharmaceuticals Ltd (2022–2026)
Year-by-year Capital Reinvestment Ratio for Emcure Pharmaceuticals Ltd from 2022 to 2026. For live market cap and broader valuation context, see Emcure Pharmaceuticals Ltd (EMCURE) total market value.
| Year | Reinvestment Ratio | Operating CF (INR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2026 | 0.42x | Rs8.51 Billion | Rs3.61 Billion | ▼ -11.3% |
| 2025 | 0.48x | Rs8.52 Billion | Rs4.07 Billion | ▲ +70.7% |
| 2024 | 0.28x | Rs10.97 Billion | Rs3.07 Billion | ▼ -48.2% |
| 2023 | 0.54x | Rs7.47 Billion | Rs4.03 Billion | ▲ +4.5% |
| 2022 | 0.52x | Rs7.68 Billion | Rs3.97 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow